Halda Therapeutics is set to present at the 43rd annual J.P. Morgan Healthcare Conference in San Francisco, CA, from January 13-16, 2025. Christian Schade, President and CEO, will provide a corporate overview, highlighting the company's innovative RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) platform and its progress in developing novel cancer therapies.
RIPTAC: A Novel Approach to Cancer Treatment
Halda Therapeutics' RIPTAC platform represents a new class of cancer therapeutics designed to address the limitations of current precision oncology medicines. Founded by Professor Craig Crews from Yale University, Halda's approach utilizes a unique "hold and kill" mechanism. This mechanism aims to overcome cancer's ability to develop bypass mechanisms of resistance, a common challenge in cancer treatment.
The RIPTAC modality works by inducing proximity between a target protein and an E3 ubiquitin ligase, leading to ubiquitination and degradation of the target protein. This targeted protein degradation offers a potential advantage over traditional small molecule inhibitors, which may only inhibit protein function without eliminating the protein altogether.
Clinical Development and Pipeline
Halda Therapeutics is advancing its lead RIPTAC programs for major solid tumor types, including prostate cancer and breast cancer. The company plans to initiate a Phase 1 clinical trial in 2025 for patients with metastatic, castration-resistant prostate cancer (mCRPC). This trial will mark a significant milestone in the development of RIPTAC therapeutics.
Addressing Unmet Needs in Cancer
The development of RIPTAC therapeutics is driven by the need for more effective cancer treatments that can overcome resistance mechanisms. Halda's pipeline includes additional RIPTAC therapeutic programs targeting unmet medical needs in various cancer types. The company's leadership team brings expertise in bifunctional drug discovery, platform innovation, and clinical development to advance these programs.
